
The Biotech Startups Podcast
ExcedrAudio
- Format:
- Podcast
- New episodes:
- Several times a week
- Typical length:
- about 30 minutes
- Latest episode:
About this show
The Biotech Startups Podcast by Excedr features weekly conversations with founders, scientists, and investors driving biotech innovation. Host Jon Chee dives into the challenges of building biotech startups, from pre-seed to IPO. New episodes every Monday and Thursday.
Covers: biotech, startups, life sciences, entrepreneurship, clinical trials, drug development, venture capital, lab equipment
Show details and episodes come from the publisher's public feed at feeds.fame.so. Last updated . Names, artwork and text belong to their publishers.
Recently on this show
Summary of recent episodes, drawn from the publisher's feed.
This podcast covers the challenges of building biotech startups, through talks with founders, scientists and investors. Recent episodes cover disease signals before symptoms, a $500 lab that launched a company, and a company that reached almost $100 million without venture funding.
Cosmos
Similar in subject
- Business Of Biotech
Both cover: biotech, drug development, clinical trials - The a16z Show
Both cover: startups, venture capital - Y Combinator
Both cover: startups, venture capital, entrepreneurship
Similar shows
Explore more
Episodes
🧬 Sales Funnels, Patents, & Cell-Based Milk: TurtleTree’s Early Bets | Fengru Lin Rerelease (2/3)
· 24 min
🧬 The Biotech Startups Podcast is powered by Excedr—helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science. As a TBSP listener, you can get exclusive perks through Excedr's partner network—special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners. "Sales is really a numbers game. It's about how many you can fill at the top of the funnel and how many you can convert over time." In this episode of The Biotech Startups Podcast, host Jon Chee continues his conversation with Fengru Lin, CEO and co-founder of TurtleTree. Fengru shares how rigorous sales training at Salesforce and entrepreneurial autonomy at Google Cloud shaped her approach to customers, investors, and organizational change—then traces how a cheese-making hobby, poor dairy supply chains, and exposure to cell-based meat and seafood startups led to TurtleTree’s founding, early patents, and strategic pivot toward precision fermentation of high-value milk proteins. Key Topics Covered: - Customer-Centric Sales Systems: How Salesforce’s CRM, service, and marketing stack turns complex sales into a data-driven funnel - Sales as a Scientific Process: Why touchpoints, funnels, and conversion metrics matter for life science tools and investor outreach - Managing the Emotional Side of Sales: Building resilience, community, and mentorship to handle constant rejection - Executive Buy-In & Organizational Change: Translating “exec connect” lessons from Salesforce to innovation adoption at TurtleTree - Hobbies as Startup Catalysts: How learning to make cheese exposed dairy supply issues and inspired a cell-based milk vision - Patents & Commercial Reality: Drafting foundational IP, avoiding “kitchen sink” claims, and pivoting to precision fermentation proteins If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Subscribe to the Podcast: Apple: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 YouTube: https://www.youtube.com/@thebiotechstartupspodcast Website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep255 Find our guest, Fengru Lin, at these links: LinkedIn: https://www.linkedin.com/in/fengru/ Website: https://www.turtletree.com/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com Intro & Outro Songs Created by OkKyojin, Owned by Excedr: Website: https://flow.page/kyojin Resources & Articles: Customer Relationship Management (CRM) Basics: https://www.salesforce.com/crm/what-is-crm Strategic Selling & Complex Stakeholder Management: https://www.salesforce.com/sales/strategic-selling Manufacturing ERP for Better Production Planning: https://kanhasoft.com/blog/manufacturing-erp-production-planning Precision Fermentation for Dairy-Identical Proteins: https://www.greenqueen.com.hk/formo-foods-precision-fermentation-casein-dairy-protein-self-gras-cheese Comparing Lab-Cultured Dairy vs Traditional Dairy: https://eureka.patsnap.com/report-comparing-lab-cultured-dairy-vs-traditional-dairy-nutritional-metrics Health Canada Approves Lab-Grown Milk: https://www.greenprophet.com/2026/06/health-canada-approves-lab-grown-milk The Best ERP Systems for Small Food Manufacturers: https://www.top10erp.org/blog/the-best-manufacturing-software-for-your-small-business Companies, Universities, & People Mentioned: Salesforce: https://www.salesforce.com Google Cloud: https://cloud.google.com TurtleTree: https://www.turtletree.com Memphis Meats / Upside Foods: https://www.upsidefoods.com BlueNalu:…
Not rated yet🧬 From Hong Kong Childhood to Global Sales: Connecting the Dots | Fengru Lin Rerelease (1/3)
· 22 min
🧬 The Biotech Startups Podcast is powered by Excedr—helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science. As a TBSP listener, you can get exclusive perks through Excedr's partner network—special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners "You can do whatever you want. You can achieve whatever you put your mind to." In this episode of The Biotech Startups Podcast, Jon Chee sits down with Fengru Lin, CEO and co-founder of TurtleTree, a biotech company using precision fermentation to produce LF+, the world’s first sustainably made lactoferrin, and ultimately reimagine how food is produced. Drawing on a nontraditional path into biotech—from Girl Guides in Singapore to sales roles in transactional security and global regulatory environments—Fengru shares how an early love of planning, operations, and people has shaped her approach to leadership and company building. Jon and Fengru explore how strict but empowering parenting in Hong Kong and Singapore instilled self-reliance, how organizing school camps and long-distance cycling trips foreshadowed operational excellence, and how early internships at places like SeaWorld, Daiwa, Nestlé, and a growing marketing agency clarified what she did and didn’t want from her career. They also discuss what it’s like to do high-stakes, detail-oriented sales across Asia in a heavily regulated industry, the importance of connecting scientists and business leaders, and why rigorous standards and regulatory thinking became foundational for TurtleTree’s commercialization strategy. Key Topics Covered: - Early Values and Self-Reliance: How a strict but supportive upbringing in Hong Kong and Singapore shaped Fengru’s confidence and drive. - Girl Guides and Leadership: Why planning camps and earning the President’s Girl Guide award honed operational and leadership skills. - Choosing Tech and Business: How studying information systems and marketing positioned her for a booming tech and finance job market. - Learning from Internships: What SeaWorld, Daiwa, Nestlé’s Milo plant, and a marketing agency taught her about work, scale, and culture. - Sales in a Regulated World: Lessons from global transactional security sales and a detail-obsessed CEO that still inform TurtleTree’s approach. - Connecting Science and Business: Why “knowing just enough” science to connect people and ideas is a superpower in biotech startups. If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Subscribe to the Podcast: Apple: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 YouTube: https://www.youtube.com/@thebiotechstartupspodcast Website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep254 Find our guest, Fengru Lin at these links: LinkedIn: https://www.linkedin.com/in/fengru/ Website: https://www.turtletree.com/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com Intro & Outro Songs Created by OkKyojin, Owned by Excedr: Website: https://flow.page/kyojin Resources & Articles: Lactoferrin in Nutrition and Immune Health (overview article): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940821 Introduction to Precision Fermentation for Food Ingredients: https://www.goodfoodinstitute.org/reports/precision-fermentation Alternative Protein and Foodtech Overview: https://gfi.org/resource/state-of-the-industry-report-alternative-proteins Regulatory Strategy Basics for Emerging Biotechs:…
Not rated yet🧬 AI in Biotech: When Sustainable Growth Replaces Hype | Mati Gill (4/4)
· 21 min
🧬 The Biotech Startups Podcast is powered by Excedr—helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science. As a TBSP listener, you can get exclusive perks through Excedr's partner network—special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners. "It's only a question of when, not if, we will see the first drug that was designed by artificial intelligence approved by the FDA." In this final episode of The Biotech Startups Podcast series, Jon Chee sits down with Mati Gill, CEO of AION Labs, to unpack where AI value is actually being created in biopharma—and what comes next. Mati lays out three pillars driving a post-hype phase of sustainable growth, explains why the industry is structurally conservative for good reasons, and shares how AION Labs is already preparing for the quantum computing wave before it arrives. Key Topics Covered: - Where AI Value Is Being Created: Why pharma has moved past the hype cycle into sustainable, evidence-based growth. - The First FDA-Approved AI-Designed Drug: Why it's when, not if—and what 60+ AI clinical programs signal about the road ahead. - Virtual Patients and Preclinical Innovation: How AI simulation of human disease biology could replace animal models that keep failing. - Why Pharma Giants Don't Get Disrupted: What Pfizer, Novartis, and Roche lasting over a century means for startups aiming to go the distance. - Building AION Labs to Outlast Its Founder: The sustainable venture studio model—and why quantum computing is next on the roadmap. - The Best Advice Mati Ever Received: A mentor's ten-year framework—and the story of reminding that mentor of his own advice. If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Subscribe to the Podcast: Apple: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 YouTube: https://www.youtube.com/@thebiotechstartupspodcast Website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep253 Find our guest, Mati Gill, at these links: LinkedIn: https://www.linkedin.com/in/matigill/?originalSubdomain=il Website: https://aionlabs.com/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com Intro & Outro Songs Created by OkKyojin, Owned by Excedr: Website: https://flow.page/kyojin Resources & Articles: Top Equipment Needs in AI-Driven Drug Discovery Labs: https://www.excedr.com/blog/top-equipment-needs-in-ai-driven-drug-discovery-labs FDA Artificial Intelligence in Drug Development: https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/artificial-intelligence-drug-development Quantum-Machine-Assisted Drug Discovery: https://www.nature.com/articles/s44386-025-00033-2 2025 Trends in Biotech Venture Capital Funding: https://www.excedr.com/blog/trends-in-biotech-venture-capital-funding Insilico Medicine's AI-Designed Drug Pipeline: https://insilico.com/about Biolojic Design — First Computationally Designed Antibody in Clinical Trial: https://biolojic.com Companies, Universities, & People Mentioned: AION Labs: https://aionlabs.com Teva Pharmaceuticals: https://www.tevapharm.com Pfizer: https://www.pfizer.com AstraZeneca: https://www.astrazeneca.com Merck: https://www.merck.com Amazon Web Services (AWS): https://aws.amazon.com Biolojic Design: https://biolojic.com Insilico Medicine: https://insilico.com Xaira Therapeutics: https://www.xaira.com BioMarin Pharmaceutical: https://www.biomarin.com Alnylam Pharmaceuticals: https://www.alnylam.com Biogen:…
Not rated yet🧬 Venture Studio Model: Building the Future of AI Drug Discovery | Mati Gill (3/4)
· 47 min
🧬 The Biotech Startups Podcast is powered by Excedr—helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science. As a TBSP listener, you can get exclusive perks through Excedr's partner network—special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners. "I said we're not signing the investment agreement until you either commit or identify a top employee that speaks the language of the customers that you're going to innovate for." Jon Chee sits down with Mati Gill, CEO of AION Labs — an Israeli venture studio backed by AstraZeneca, Merck, Pfizer, Teva, AWS, and the Israel Biotech Fund. Mati breaks down how AION Labs builds AI-native pharma companies from the ground up: industry-grade problem statements, multidisciplinary teams, and pharma partner POC commitments locked in before a startup is formed. Key Topics Covered: - Israel's Bio-Convergence Policy: How the IIA identified a market failure and built the incentive structure behind AION Labs. - Venture Studio vs. Traditional VC: Why AION Labs builds deal flow systematically and why pharma R&D expert time outweighs capital. - Problem Statement Discipline: What makes a challenge worth building a company around, and why POC commitment must come first. - Multidisciplinary Teams: The lesson from AION Labs' first shutdown — cross-disciplinary hiring is required before any investment closes. - Operational Infrastructure First: How pre-approved MSAs and a shared AWS cloud give startups pharma data access on day one, not year two. - Platform vs. Single Asset: Why AION Labs only backs platform technologies and how Insitro's Combinable acquisition proves it. If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Subscribe to the Podcast: Apple: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 YouTube: https://www.youtube.com/@thebiotechstartupspodcast Website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep252 Find our guest, Mati Gill, at these links: LinkedIn: https://www.linkedin.com/in/matigill/?originalSubdomain=il Website: https://aionlabs.com/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com Intro & Outro Songs Created by OkKyojin, Owned by Excedr: Website: https://flow.page/kyojin Resources & Articles: AION Labs — Wikipedia Overview: https://en.wikipedia.org/wiki/AION_Labs Israel's Bio-Convergence Strategy: https://innovationisrael.org.il/en/article/bio-convergence-israels-next-growth-engine/ Hatch-Waxman Act Overview: https://phrma.org/blog/40-years-of-hatch-waxman-what-is-the-hatch-waxman-act How Biotech Partnerships Support R&D: https://www.excedr.com/blog/how-biotech-partnerships-support-research PhaseV Raises $50M for AI Clinical Trials: https://www.mobihealthnews.com/news/phasev-scores-50m-ai-clinical-trial-platform What Corporate Investors Look for in Life Sciences Startups: https://www.excedr.com/blog/what-corporate-investors-look-for-in-life-sciences-startups Companies, Universities, & People Mentioned: AION Labs: https://aionlabs.com/ Teva Pharmaceuticals: https://www.tevapharm.com/ Weizmann Institute of Science: https://www.weizmann.ac.il/pages/ BioMed X Institute: https://bmedx.com/ Israel Innovation Authority: https://innovationisrael.org.il/en/ Pfizer: https://www.pfizer.com/ AstraZeneca: https://www.astrazeneca.com/ Merck (Germany): https://www.merckgroup.com/ Amazon Web Services: https://aws.amazon.com/ Israel Biotech Fund: https://ibf.fund/ aMoon:…
Not rated yet🧬 From Law School to Teva: Learning a 45,000-Person Organization | Mati Gill (2/4)
· 36 min
🧬 The Biotech Startups Podcast is powered by Excedr—helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science. As a TBSP listener, you can get exclusive perks through Excedr's partner network—special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners. "There's one thing that we haven't been able to innovate, which is how to make the day longer than 24 hours. So it's all what you give up." In this episode of The Biotech Startups Podcast, Jon Chee sits down with Mati Gill, CEO of AION Labs. Mati traces his path from juggling a minister's bureau with Israeli law school to joining Teva as an intern with no private-sector experience, then learning a 45,000-person org from the chart up — until Teva's financial crisis handed him the mandate to build the innovation program that became AION Labs. Key Topics Covered: - Juggling Government and Law School: Why Mati said yes to a minister's office mid-law-school. - A Health Crisis as a Reset: Being wounded in a terrorist attack and the priorities it forced. - Starting at the Bottom of Teva: The deliberate choice to intern at a company he knew nothing about. - Learning a 45,000-Person Org: Coffee with the former deputy R&D head twice a week, plus a walk through the org chart. - Never Waste a Crisis: How Teva's financial collapse gave Mati the mandate for a new innovation program. - Industry-Academia Partnerships: Where collaborations break down and what the Weizmann model gets right. If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Subscribe to the Podcast: Apple: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 YouTube: https://www.youtube.com/@thebiotechstartupspodcast Website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep251 Find our guest, Mati Gill at these links: LinkedIn: https://www.linkedin.com/in/matigill/?originalSubdomain=il Website: https://aionlabs.com/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com Intro & Outro Songs Created by OkKyojin, Owned by Excedr: Website: https://flow.page/kyojin Resources & Articles: Biotech Partnerships: How Industry and Academia Work Together: https://www.excedr.com/blog/how-biotech-partnerships-support-research The Story of Copaxone — From Weizmann Lab to FDA Approval: https://wis-wander.weizmann.ac.il/life-sciences/cop-1-copaxone%C2%AE-story-drug Industry-Academia Drug Discovery Collaborations: https://blog.drugbank.com/the-collaboration-between-industry-and-academia-in-drug-development/ Brian Chesky on AI Founder Mode — Invest Like the Best, Ep. 471: https://podcasts.apple.com/us/podcast/brian-chesky-ai-founder-mode/id1154105909?i=1000766196703 Companies, Universities, & People Mentioned: Teva Pharmaceuticals: https://www.tevapharm.com AION Labs: https://aionlabs.com Weizmann Institute of Science: https://www.weizmann.ac.il Danaher Corporation: https://www.danaher.com Thermo Fisher Scientific: https://www.thermofisher.com Airbnb: https://www.airbnb.com Donna Baron (Dana Bar-On), Head of Academic Collaborations, Teva R&D: https://www.linkedin.com/in/barondana Jeremy Levin, Former CEO of Teva: https://en.wikipedia.org/wiki/Jeremy_Levin Kåre Schultz, Former CEO of Teva: https://en.wikipedia.org/wiki/K%C3%A5re_Schultz Eli Hurvitz, Founder of Modern Teva: https://en.wikipedia.org/wiki/Eli_Hurvitz Yair Benita, CTO of AION Labs: https://www.linkedin.com/in/ybenita Timestamps: 00:00 Intro 01:56 Three Life Anchors and the Decision to Say…
Not rated yet🧬 The Rule of Three: Career, Family & One Other Thing | Mati Gill (1/4)
· 24 min
🧬 The Biotech Startups Podcast is powered by Excedr—helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science. As a TBSP listener, you can get exclusive perks through Excedr's partner network—special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners. "Getting tough feedback, when it comes from a place of someone that wants to help you but is willing to tell you the brutal truth to help you learn and help you grow, is a gift, and not everyone is capable of doing that." In this episode of The Biotech Startups Podcast, Jon Chee sits down with Mati Gill, CEO of AION Labs—a first-of-its-kind AI venture studio backed by Teva, Pfizer, AstraZeneca, Merck, and Amazon Web Services. Before AION Labs, Mati spent six years in the IDF, ran a minister's bureau, and rose from legal intern to global legal COO at Teva over more than a decade. Part one covers the formative years: moving from Columbus, Ohio to Jerusalem at 12, extending military service by three years, and the two teachers who handed him D's and changed how he works. Key Topics Covered: - Columbus to Jerusalem: How a trial year in Israel at age 12 became a permanent, repeatedly chosen life. - The Rule of Three: Mati's framework for building a career, prioritizing family, and committing to one other thing—without compromise. - Two Teachers, Two D's: The English teacher who walked in like Robin Williams and the constitutional law professor who handed Mati a 60, and what both taught him about coasting. - Six Years in the IDF: Why Mati signed up for three years beyond mandatory service and how those values still drive every major career decision. - Law as a Foundation: How studying under Professor Amnon Rubinstein—a Knesset member who helped draft Israel's civil rights bills—built the analytical foundation Mati still draws on today. If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Subscribe to the Podcast: Apple: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 Youtube: https://www.youtube.com/@thebiotechstartupspodcast Website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep250 Find our guest, Mati Gill at these links: LinkedIn: https://www.linkedin.com/in/matigill/?originalSubdomain=il Website: https://aionlabs.com/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com Intro & Outro Songs Created by OkKyojin, Owned by Excedr: Website: https://flow.page/kyojin Resources & Articles: AION Labs — AI Venture Studio Overview: https://aionlabs.com/ Amnon Rubinstein — Wikipedia: https://en.wikipedia.org/wiki/Amnon_Rubinstein Israel Innovation Authority — AI and Bioconvergence Programs: https://innovationisrael.org.il/en/ Top Equipment Needs in AI-Driven Drug Discovery Labs: https://www.excedr.com/blog/top-equipment-needs-in-ai-driven-drug-discovery-labs 20 Biotech Accelerators to Check Out: https://www.excedr.com/resources/biotech-accelerators How to Spin Out of Academia and Into a Startup: https://www.excedr.com/resources/how-to-spin-out-of-academia-and-into-a-startup Artificial Intelligence in the Development of New Drugs — Israel Innovation Authority: https://innovationisrael.org.il/en/drugdiscoveryai2024/ Companies, Universities, & People Mentioned: AION Labs: https://aionlabs.com/ Teva Pharmaceuticals: https://www.tevapharm.com Pfizer: https://www.pfizer.com AstraZeneca: https://www.astrazeneca.com Merck: https://www.merck.com Amazon Web Services: https://aws.amazon.com Israel…
Not rated yet🧬 From Reactive Data to Predictive Intelligence: Inside Convoke's Platform | Alex Telford (4/4)
· 24 min
🧬 The Biotech Startups Podcast is powered by Excedr—helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science. As a TBSP listener, you can get exclusive perks through Excedr's partner network—special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners. "You could have an academic with an idea for a drug, hand it off to a system, and the system could do all the knowledge work required to take that drug through the development and regulatory process—and get it to market. We're very long way away from that. But that's the future we want to work towards." In part four, Alex Telford, founder of Convoke, covers the platform architecture and roadmap. He walks through Convoke's modular system—building validated structured datasets from trial registries, regulatory filings, and patents, then stitching them with workflow tools for competitive intelligence and document generation. He breaks down how pharma and biotech customers engage differently, why an "everything app" is a trap, and how Convoke is moving from reactive data storage toward proactive, predictive intelligence. Key Topics Covered: - Content Quality in the LLM Era: Why spending six months writing the definitive piece beats volume publishing—and how the internet's sorting mechanism rewards genuinely excellent work. - Convoke's Platform Architecture: Building infrastructure for autonomous drug development through validated datasets, workflow tools, and embedded customer partnerships. - Big Pharma vs. Biotech Go-to-Market: Why scope of influence—not culture—determines AI adoption speed, and why biotechs move faster despite smaller budgets. - The Everything App Trap: Why being opinionated about where you deliver value matters more than building every feature. - From Reactive to Proactive Intelligence: Moving from dataset creation to a system that continuously ingests data and makes autonomous recommendations, starting with trial site selection. If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Links: Subscribe to the Podcast: Apple: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 YouTube: https://www.youtube.com/@thebiotechstartupspodcast Website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep249 Find our guest, Alex Telford at these links: LinkedIn: https://www.linkedin.com/in/alexander-telford/ Website: https://www.convoke.bio/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com Intro & Outro Songs Created by OkKyojin, Owned by Excedr: Website: https://flow.page/kyojin Resources & Articles: The Agentic Era: Why Biopharma Must Embrace AI That Acts, Not Just Informs: https://pmc.ncbi.nlm.nih.gov/articles/PMC12048886/ What Is Retrieval Augmented Generation (RAG)?: https://www.databricks.com/blog/what-is-retrieval-augmented-generation AI for Clinical Trial Site Selection: https://pplelabs.com/ai-for-clinical-trial-site-selection/ Knowledge Management in Pharmaceutical Companies: https://pharmacores.com/knowledge-management-in-pharmaceutical-industry/ Convoke Raises $8.6M to Build the AI OS for Biopharma: https://www.prnewswire.com/news-releases/convoke-raises-8-6m-to-build-the-ai-operating-system-for-biopharma-302533188.html Acquired Podcast: https://www.acquired.fm/ Companies, Universities, & People Mentioned: Convoke: https://www.convoke.bio/ AION Labs: https://aionlabs.com Excedr: https://www.excedr.com Mati Gill (CEO, AION Labs): https://www.linkedin.com/in/matigill…
Not rated yet🧬 Pharma's Coordination Tax & the 2 Paths That Could Actually Disrupt It | Alex Telford (3/4)
· 28 min
🧬 The Biotech Startups Podcast is powered by Excedr—helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science. As a TBSP listener, you can get exclusive perks through Excedr's partner network—special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners. "No. I do think you do need to recreate the orchestration. I think you have to retool the organization around these new technologies, and some will not be able to rearchitecture, and they will die. Some will be able to rearchitecture and they will thrive." In this episode, Jon Chee sits down with Alex Telford, founder of Convoke, to examine why large pharma resists AI transformation. Drawing on seven years at Charles River Associates, Alex maps the coordination tax of siloed orgs, the tacit knowledge lost when experts retire, and why software efficiency is the wrong axis to compete on. His frame: factory electrification — the gains don't arrive until you redesign the whole org around the technology. Key Topics Covered: - Re-architecting Around General-Purpose Technology: Why pharma's AI gains won't arrive until the org is redesigned around it. - The Tacit Knowledge Problem: Why decades of regulatory expertise walks out the door when a scientist retires. - The Two Paths That Could Disrupt Pharma: Why differentiated target discovery or vertically integrated DTC beat competing on software efficiency. - LillyDirect and the Consumer Health Bundle: How Eli Lilly's DTC platform hints at a new pharma business model. - Signal-to-Noise Beats Raw Data: Why more data often makes LLM systems worse, and what Renaissance Technologies' data-cleaning edge was actually about. - Writing in Public Built a Company: How a blog post led to a podcast, a cofounder email, and Convoke's $8.6M seed round. If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Links: Subscribe to the Podcast: Apple: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 Youtube: https://www.youtube.com/@thebiotechstartupspodcast Website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep248 Find our guest, Alex Telford at these links: LinkedIn: https://www.linkedin.com/in/alexander-telford/ Website: https://www.convoke.bio/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com Intro & Outro Songs Created by OkKyojin, Owned by Excedr: Website: https://flow.page/kyojin Resources & Articles: The Dynamo and the Computer — Paul David on electrification and the productivity paradox: https://www.almendron.com/tribuna/wp-content/uploads/2018/03/the-dynamo-and-the-computer-an-historical-perspective-on-the-modern-productivity-paradox.pdf General-Purpose Technologies (Wikipedia): https://en.wikipedia.org/wiki/General-purpose_technology King – Man + Woman = Queen: The Mathematics of Computational Linguistics: https://www.technologyreview.com/2015/09/17/166211/king-man-woman-queen-the-marvelous-mathematics-of-computational-linguistics/ Convoke Raises $8.6M to Build the AI OS for Biopharma: https://www.convoke.bio/blog/announcing-our-seed-fundraise Pfizer and Lilly Move Into Direct-to-Consumer Pharma: https://www.biopharmadive.com/news/pfizer-eli-lilly-direct-to-consumer-glp-1/716866/ Companies, Universities, & People Mentioned: Convoke: https://www.convoke.bio/ Charles River Associates (CRA): https://www.crai.com Alnylam Pharmaceuticals: https://www.alnylam.com BioMarin Pharmaceutical: https://www.biomarin.com Eli Lilly: https://www.lilly.com Hims &…
Not rated yet🧬 AI Psychosis, Coordination Tax & the Limits of LLMs | Alex Telford (2/4)
· 46 min
🧬 The Biotech Startups Podcast is powered by Excedr—helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science. As a TBSP listener, you can get exclusive perks through Excedr's partner network—special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners. "The models are like this bunch of fractured entities — depending on how you prompt them, you can access one fractured space or another." In this episode of The Biotech Startups Podcast, Jon Chee sits down with Alex Telford, founder of Convoke, who spent nearly seven years in biopharma strategy consulting before what he calls "AI psychosis" set him on a different path. Alex traces the arc from biochemistry at Bristol and synthetic biology at UCL to discovering consulting existed only after graduating, joining a boutique Swiss firm two weeks before it was acquired, and learning one core lesson: clients want a recommendation to push back on, not a data dump. Key Topics Covered: - The Slot Machine Problem: Why LLMs fail to get it right the first time — data scarcity, epistemic unknowability, and model architecture. - AI's Good Fits in Life Science: Where LLMs work in biopharma — document analysis, regulatory submissions, clinical data structuring — and where they break down in pure discovery. - What a Harness Is: A plain-language breakdown of AI operating environments, with Cursor and Harvey as examples. - The Consultant's Real Job: Why effective strategy means reducing decision friction, not dumping analysis — and why LLMs can't thread that needle yet. - Coordination Tax in Pharma: How siloed functions and unknowable drug biology make decisions stall — and what AI might actually fix. If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Links: Subscribe to the Podcast: Apple: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 YouTube: https://www.youtube.com/@thebiotechstartupspodcast Website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep247 Find our guest, Alex Telford at these links: LinkedIn: https://www.linkedin.com/in/alexander-telford/ Website: https://www.convoke.bio/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com Intro & Outro Songs Created by OkKyojin, Owned by Excedr: Website: https://flow.page/kyojin Resources & Articles: AlphaFold: Highly Accurate Protein Structure Prediction: https://www.nature.com/articles/s41586-021-03819-2 AI-Generated Poetry Is Indistinguishable from Human Poetry: https://www.nature.com/articles/s41598-024-76900-1 LLMs in Drug Discovery and Development — A Primer: https://pmc.ncbi.nlm.nih.gov/articles/PMC11984503/ Top Equipment Needs in AI-Driven Drug Discovery Labs: https://www.excedr.com/blog/top-equipment-needs-in-ai-driven-drug-discovery-labs Electrification and the Productivity Lag — Why Retooling Takes Decades: https://www.weforum.org/stories/2019/04/the-latest-technology-isnt-enough-you-need-the-business-model-to-go-with-it/ PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy: https://pmc.ncbi.nlm.nih.gov/articles/PMC8440961/ Companies, Universities, & People Mentioned: Convoke: https://www.convoke.bio/ Charles River Associates (CRA): https://www.crai.com Cursor: https://cursor.com Harvey AI: https://www.harvey.ai AppLovin: https://www.applovin.com University of Bristol: https://www.bristol.ac.uk University College London (UCL): https://www.ucl.ac.uk Maged Ahmed (Co-Founder, Convoke): https://www.linkedin.com/in/mageda Vikas…
Not rated yet🧬 From Expat Kid to Founder: Science, Curiosity & the Long Road to Conviction | Alex Telford (1/4)
· 22 min
🧬 The Biotech Startups Podcast is powered by Excedr—helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science. As a TBSP listener, you can get exclusive perks through Excedr's partner network—special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners. "We don't understand biology. It's so complex that it's not engineerable, really, in any useful way." In this episode of The Biotech Startups Podcast, Jon Chee sits down with Alex Telford, founder of Convoke, who raised $8.6 million to build the AI-native operating system for biopharma. Part one traces his path from an expat childhood across Switzerland, Germany, and Spain — shaped by international schools, disappearing friendships, and a New Scientist subscription — through biochemistry at Bristol and into a synthetic biology master's at UCL that promised biological engineering and delivered toggle switches. Key Topics Covered: - Expat Childhood and Comfort with Impermanence: Growing up in international schools where best friends disappeared with each relocation built a tolerance for instability that made leaving a stable consulting career feel manageable. - Science as Self-Directed Curiosity: No scientists in the family — just New Scientist, National Geographic, and two teachers who steered him toward biochemistry. - Choosing University on Personal, Not Academic, Grounds: Applied to Bristol because his mum had a friend there, York because his grandmother lived there. Got into Oxford. Went to Bristol. - What Wet Lab Work Actually Feels Like: Three months of Western blots on red blood cell proteins — slow, hard to debug, and disconnected from application. - Synthetic Biology's Gap Between Promise and Practice: The UCL master's offered biological robots and re-engineered supply chains. The actual work was genetic toggle switches that mutate within a few divisions. If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Links: Subscribe to the Podcast: Apple: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 YouTube: https://www.youtube.com/@thebiotechstartupspodcast Website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep246 Find our guest, Alex Telford at these links: LinkedIn: https://www.linkedin.com/in/alexander-telford/ Website: https://www.convoke.bio/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com Intro & Outro Songs Created by OkKyojin, Owned by Excedr: Website: https://flow.page/kyojin Resources & Articles: Why Some Biotech Startups Struggle to Scale: https://www.excedr.com/resources/why-some-biotech-startups-struggle-to-scale IB Diploma Programme: https://en.wikipedia.org/wiki/IB_Diploma_Programme MRC Laboratory of Molecular Biology — History: https://mrclmb.ac.uk/about/history/ Genetic Circuits in Synthetic Biology: Broadening the Toolkit: https://www.frontiersin.org/journals/synthetic-biology/articles/10.3389/fsybi.2025.1548572/full Artificial Intelligence in Drug Discovery and Development: https://pmc.ncbi.nlm.nih.gov/articles/PMC7577280/ Companies, Universities, & People Mentioned: Convoke: https://www.convoke.bio/ Dow Chemical: https://www.dow.com University of Bristol: https://www.bristol.ac.uk University College London (UCL): https://www.ucl.ac.uk Kleiner Perkins: https://www.kleinerperkins.com Dimension Capital: https://www.dimensioncap.com/ Leigh Marie Braswell (Partner, Kleiner Perkins): https://www.linkedin.com/in/leigh-marie-braswell Nan Li (Managing…
Not rated yet